Lung Cancer
Volume 69, Issue 3 , Pages 279-283 , September 2010

PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers

  • Guang Jin

      Affiliations

    • Department of Biochemistry and Molecular Biology, School of Medicine, Kyungpook National University, Dong In 2Ga 101, Daegu 700-422, Republic of Korea
    • Department of Pharmacology, Yanbian University School of Basic Medicine, Yanji 133000, Jilin Province, China
    • ,
  • Min Jung Kim

      Affiliations

    • Department of Biochemistry and Molecular Biology, School of Medicine, Kyungpook National University, Dong In 2Ga 101, Daegu 700-422, Republic of Korea
    • ,
  • Hyo-Sung Jeon

      Affiliations

    • Department of Biochemistry and Molecular Biology, School of Medicine, Kyungpook National University, Dong In 2Ga 101, Daegu 700-422, Republic of Korea
    • Cancer Research Institute, School of Medicine, Kyungpook National University, Dong In 2Ga 101, Daegu 700-422, Republic of Korea
    • ,
  • Jin Eun Choi

      Affiliations

    • Department of Biochemistry and Molecular Biology, School of Medicine, Kyungpook National University, Dong In 2Ga 101, Daegu 700-422, Republic of Korea
    • ,
  • Dong Sun Kim

      Affiliations

    • Department of Anatomy, School of Medicine, Kyungpook National University, Dong In 2Ga 101, Daegu 700-422, Republic of Korea
    • ,
  • Eung Bae Lee

      Affiliations

    • Department of Thoracic Surgery, Kyungpook National University Hospital, Samduk 2Ga 50, Daegu 700-412, Republic of Korea
    • ,
  • Sung Ick Cha

      Affiliations

    • Department of Internal Medicine, Kyungpook National University Hospital, Samduk 2Ga 50, Daegu 700-412, Republic of Korea
    • ,
  • Ghil Sook Yoon

      Affiliations

    • Department of Pathology, Kyungpook National University Hospital, Samduk 2Ga 50, Daegu 700-412, Republic of Korea
    • ,
  • Chang Ho Kim

      Affiliations

    • Department of Internal Medicine, Kyungpook National University Hospital, Samduk 2Ga 50, Daegu 700-412, Republic of Korea
    • ,
  • Tae Hoon Jung

      Affiliations

    • Department of Internal Medicine, Kyungpook National University Hospital, Samduk 2Ga 50, Daegu 700-412, Republic of Korea
    • ,
  • Jae Yong Park

      Affiliations

    • Department of Biochemistry and Molecular Biology, School of Medicine, Kyungpook National University, Dong In 2Ga 101, Daegu 700-422, Republic of Korea
    • Cancer Research Institute, School of Medicine, Kyungpook National University, Dong In 2Ga 101, Daegu 700-422, Republic of Korea
    • Department of Internal Medicine, Kyungpook National University Hospital, Samduk 2Ga 50, Daegu 700-412, Republic of Korea
    • Corresponding Author InformationCorresponding author at: Department of Internal Medicine, Kyungpook National University Hospital, Samduk 2Ga 50, Daegu 700-412, Republic of Korea. Tel.: +82 53 420 5536; fax: +82 53 426 2046.

Received 2 July 2009 ,Revised 28 October 2009 ,Accepted 20 November 2009.

References 

  1. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol. 2001;2:127–137
  2. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501
  3. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003;197:157–168
  4. Downward J. Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22
  5. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science. 1997;275:1943–1947
  6. Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003;22:183–198
  7. Li L, Ross AH. Why is PTEN an important tumor suppressor?. J Cell Biochem. 2007;102:1368–1374
  8. Liu W, Zhou Y, Reske SN, Shen C. PTEN mutation: many birds with one stone in tumorigenesis. Anticancer Res. 2008;28:3613–3620
  9. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 1997;57:4997–5000
  10. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997;57:4736–4738
  11. Forgacs E, Biesterveld EJ, Sekido Y, Fong K, Muneer S, Wistuba II, et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene. 1998;17:1557–1565
  12. Kohno T, Takahashi M, Manda R, Yokoda J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer. 1998;22:152–156
  13. Yokomizo A, Tindall DJ, Drabkin H, Gemmill R, Franklin W, Yang P, et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene. 1998;17:475–479
  14. Virmani AK, Fong KM, Kodagoda D, Mclntire D, Hung J, Tonk V, et al. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer. 1998;21:308–319
  15. An Q, Liu Y, Gao Y, Huang J, Fong X, Liu L, et al. Deletion of tumor suppressor genes in Chinese non-small cell lung cancer. Cancer Lett. 2002;184:189–195
  16. Georgescu MM, Kirsch K, Akagi T, Shishido T, Hanafusa H. The tumor suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA. 1999;96:10182–10187
  17. Vazquez F, Devreotes P. Regulation of PTEN functions as PIP3 gatekeeper through membrane interaction. Cell Cycle. 2006;5:1523–1527
  18. Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y, et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene. 2007;26:5911–5918
  19. Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, et al. Mutations in the LKB1 tumor suppressor are frequently detected in tumors from Caucasian but not Asian lung cancer patients. Br J Cancer. 2008;99:245–252
  20. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339–346
  21. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumors cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 2003;22:2812–2822
  22. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–354
  23. Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, Matsuda K, et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer. 2005;92:1711–1719
  24. Reily GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006;12:7232–7241
  25. Rosell R, Taron M, Reguart N, Isla D, Moran T. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res. 2006;12:7222–7231
  26. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, et al. Regulation of PTEN transcription by p53. Mol Cell. 2001;8:317–325

PII: S0169-5002(09)00589-3

doi: 10.1016/j.lungcan.2009.11.012

Lung Cancer
Volume 69, Issue 3 , Pages 279-283 , September 2010

Article Tools

* Image Usage & Resolution